Viking Therapeutics, Inc.
NASDAQ: VKTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Brian Lian
- Employees
- 45
- Headquarters
- San Diego, United States
- IPO year
- 2015
- Market cap
- $3.5B
- Website
- https://www.vikingtherapeutics.com
Loading VKTX…
Loading profile data…Frequently asked questions about VKTX
What does Viking Therapeutics, Inc. (VKTX) do?
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound i...
Where does VKTX trade?
Viking Therapeutics, Inc. (VKTX) trades on the NASDAQ Capital Market.
What sector is VKTX in?
Viking Therapeutics, Inc. (VKTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Viking Therapeutics, Inc.?
Brian Lian is the chief executive officer of Viking Therapeutics, Inc. (VKTX).
Where is Viking Therapeutics, Inc. headquartered?
Viking Therapeutics, Inc. is headquartered in United States.
Does VKTX pay a dividend?
Viking Therapeutics, Inc. (VKTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VKTX go public?
Viking Therapeutics, Inc. (VKTX) completed its initial public offering in 2015.